Modified GM-CSF Protein for Crohn's Disease Autoantibody Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic tools for inflammatory bowel disease (IBD), particularly Crohn's Disease, are inadequate due to the heterogeneity of the disease and the lack of precise diagnostic markers, with existing treatments failing to effectively target the underlying immunological mechanisms involving Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) and its autoantibodies.
Innovation Solution
Development of a composition comprising post-translationally modified GM-CSF protein and methods for diagnosing IBD, including detecting anti-GM-CSF autoantibodies, and administering recombinant GM-CSF to treat Crohn's Disease, utilizing genetically engineered variants of GM-CSF that escape neutralization by autoantibodies and are effective in inducing normal signaling cascades.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for IBD, then general disease detection is possible, but early prediction and precise diagnosis are insufficient
Solution Approach 1:
The patent applies preliminary action by detecting anti-GM-CSF autoantibodies in subjects before clinical symptoms of Crohn's Disease appear. The method identifies subjects at risk years before disease onset, enabling early intervention and treatment planning before the disease fully develops.
2Reliability
If standard GM-CSF therapy is administered, then anti-inflammatory effects are achieved, but neutralization by autoantibodies reduces treatment efficacy
Solution Approach 1:
The patent converts the harmful neutralization effect into a beneficial diagnostic tool. By detecting the presence of anti-GM-CSF autoantibodies, the method identifies subjects who would respond differently to therapy, allowing for personalized treatment selection that accounts for the neutralizing effect rather than treating all patients uniformly.
Solution Approach 2:
The patent applies local quality by differentiating treatment approaches based on the specific condition of each patient's immune system. Subjects with anti-GM-CSF autoantibodies receive different therapeutic management compared to those without, tailoring the treatment quality to the local immunological context of each patient.
3Adaptability or versatility
If IBD treatment targets general inflammation, then broad anti-inflammatory effects are achieved, but specific immunological mechanisms involving GM-CSF are not effectively targeted
Solution Approach 1:
The patent segments the IBD patient population into distinct groups based on the presence or absence of anti-GM-CSF autoantibodies. This segmentation allows for targeted therapeutic strategies specific to each subgroup, moving away from uniform treatment approaches toward personalized medicine that addresses the specific immunological mechanisms of each patient.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach allows for early prediction and treatment of Crohn's Disease by identifying anti-GM-CSF autoantibodies years before disease onset and providing a therapeutic option that bypasses neutralization, potentially improving treatment efficacy and disease management.
Implementation Method 1
genetically engineered variants of GM-CSF that escape neutralization by autoantibodies and are effective in inducing normal signaling cascades
Implementation Method 2
detecting anti-GM-CSF autoantibodies... providing a therapeutic option that bypasses neutralization
Data Source
AI summary
The present disclosure relates to a composition comprising a post-translationally modified Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) protein. The disclosure further relates to methods of preventing or treating Crohn's Disease and/or a condition resulting from Crohn's Disease in a subject. The disclosure further relates to methods for diagnosing and/or predicting severity of and/or treating Crohn's Disease in a subject. Also disclosed are methods for diagnosing inflammatory bowel disease in a subject and methods for diagnosing a pre-disease state of Crohn's Disease in a subject.